Growth Hormone & IGF-1

Growth hormone (GH) is produced by your pituitary gland and drives most of its effects through IGF-1 (insulin-like growth factor 1), produced mainly by your liver in response to GH signaling. GH declines by roughly 1–2% per year after your mid-twenties, which is the core reason there’s so much interest in supporting this pathway as people age.

Your pituitary’s GH release is actually governed by three separate hormones working together: GHRH (which stimulates release), somatostatin (which inhibits it), and ghrelin (which amplifies it). This three-way balance is the exact architecture our GH-axis peptide protocols — Sermorelin, Ipamorelin, Tesamorelin, and Hexarelin — are designed to work within, rather than override.

Adequate protein intake is essential, since GH and IGF-1 both act primarily by driving protein synthesis — the raw material has to be available for the signal to matter. Zinc and vitamin B6 support pituitary GH synthesis and signaling directly, and magnesium is required for the cAMP-based signaling cascade GHRH-type peptides depend on. Sleep quality is arguably the single most important non-pharmacological factor of all, since the majority of your body’s natural GH release happens during deep, slow-wave sleep.

Recombinant human growth hormone is an FDA-approved prescription therapy for specific diagnosed conditions. Our GH-axis peptide protocols (linked above) work by stimulating the body’s own GH release rather than administering GH directly — active or suspected malignancy is treated as an absolute contraindication for all of these compounds, and cancer screening is appropriate before starting any GH-axis protocol. See each peptide’s page for its specific research and regulatory status.

Growth hormone and IGF-1 have well-documented physiological roles in promoting lipolysis and protein synthesis. Recombinant growth hormone itself is FDA-approved for specific diagnosed conditions. Our GH-axis peptide protocols work by stimulating the body’s own GH release rather than administering GH directly — see the FAQ on those individual peptide pages for their specific research and regulatory status.

IGF-1 is measured via blood test and used clinically as a more stable marker of overall GH-axis activity than GH itself, which is released in pulses. Our providers monitor IGF-1 as a core part of any GH-axis peptide protocol, keeping levels within an age-appropriate range.